Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.60 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9707103 | 0.93 | MLYCD (0.54) | MLYCDCES2CES1KMT2ACYP1A2 | |
| SCHEMBL13694024 | 0.83 | MLYCD (0.48) | MLYCDCYP1A2CYP2C19RAB9ANPC1 | |
| SCHEMBL1303906 | 0.82 | MLYCD (0.57) | MLYCDKMT2ACA1CA2RAB9A | |
| SCHEMBL1012521 | 0.82 | MLYCD (0.57) | MLYCDKMT2ARAB9ANPC1MEN1 | |
| SCHEMBL870352 | 0.82 | MLYCD (0.57) | MLYCDCES2CES1KMT2AMEN1 | |
| SCHEMBL22531823 | 0.82 | MLYCD (0.57) | MLYCDKMT2ACA1CA2NPC1 | |
| SCHEMBL623946 | 0.80 | PKM (0.56) | MLYCDCES2CES1CYP1A2CYP2C19 | |
| SCHEMBL3305455 | 0.80 | ALDH1A1 (0.57) | MLYCDKMT2ACYP1A2CYP2C19RAB9A | |
| SCHEMBL286256 | 0.80 | CES2 (0.57) | MLYCDCES2CES1CYP1A2CYP2C19 | |
| SCHEMBL6616024 | 0.80 | MLYCD (0.56) | MLYCDKMT2ACYP1A2CYP2C19CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624043-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260116883-A1 | CRYSTALLINE FORMS OF (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1- METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE AND METHODS OF MAKING | BLUEPRINT MEDICINES CORP (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4702025-A1 | BICYCLIC HETEROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| US-12252494-B2 | Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis | BLUEPRINT MEDICINES CORPORATION (US) | 2025-03-18 | — | — | US | disclosed |
| CN-113966334-B | Crystalline forms of compound (I) | 缆图药品公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024223715-A1 | BICYCLIC HETEROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-31 | — | — | WO | disclosed |
| US-20240317757-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024172156-A1 | COMPOUND HAVING BRASSINOSTEROID-LIKE ACTIVITY | 国立大学法人東海国立大学機構 | 2024-08-22 | — | — | WO | disclosed |
| US-11999744-B2 | Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| WO-1997005878-A1 | 2,5-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 1997-02-20 | — | — | WO | disclosed |
| US-5494918-A | ANTICHOLESTEROL AGENTS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0667855-A4 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS. | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0667855-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1995-08-23 | — | — | EP | disclosed |
| WO-1995003297-A1 | IMIDAZOLES FOR TREATING CYTOKINE MEDIATED DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
| US-5385912-A | Hypocholesterolemic or hypolipidemic agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1994011342-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1994-05-26 | — | — | WO | disclosed |
| EP-0370300-B1 | Cyclopropyl-substituted azolyl methyl carbinoles, process for their preparation and their use as therapeutic agents | BAYER AG (DE) | 1994-04-06 | — | — | EP | disclosed |
| US-5288751-A | [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
| US-5059615-A | Treatment of mycoses | BAYER AKTIENGESELLSCHAFT (DE) | 1991-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317757-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, MSH2 | MLYCD 1071/4885CES2 3491/4885CES1 2401/4885 |
| US-12624043-B2 | Compositions useful for treating disorders related to kit | KIT, RET, SLC26A4 | MLYCD 1756/4885CES2 2872/4885CES1 3542/4885 |
| US-11999744-B2 | Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making | PDGFRA, KIT, PDGFRB | MLYCD 4005/4885CES2 4051/4885CES1 2648/4885 |
| US-20260116883-A1 | CRYSTALLINE FORMS OF (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1- METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE AND METHODS OF MAKING | PDGFRA, KIT, PDGFRB | MLYCD 3697/4885CES2 4469/4885CES1 3199/4885 |
| US-12252494-B2 | Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis | KIT, PDGFRA, PDGFRB | MLYCD 4157/4885CES2 3811/4885CES1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.